AAPL 190.415 0.3663% MSFT 422.65 -0.1016% GOOG 175.36 0.8512% GOOGL 174.14 0.9449% AMZN 185.71 -0.1505% NVDA 943.46 -0.3001% META 473.555 -1.6582% TSLA 174.87 0.5058% TSM 154.06 -0.977% LLY 776.1758 -1.3779% V 280.145 -0.2972% AVGO 1436.4972 0.0228% JPM 204.205 1.0366% UNH 522.225 0.9033% NVO 133.03 -1.2105% WMT 63.485 6.109% LVMUY 170.79 -0.2511% XOM 117.87 -0.5988% LVMHF 855.728 -0.1473% MA 461.6867 0.805%
Last update at 2024-05-16T16:48:00Z
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Income before tax | -203.46600M | -228.27400M | -154.02800M | -139.54900M | -107.37700M |
| Minority interest | - | - | - | - | - |
| Net income | -204.61800M | -217.86300M | -152.09800M | -139.93100M | -107.66900M |
| Selling general administrative | 189.74M | 212.95M | 135.90M | 103.27M | 80.13M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 89.73M | 84.23M | 51.71M | 28.69M | 6.96M |
| Reconciled depreciation | - | 16.51M | 9.75M | 6.68M | 6.11M |
| Ebit | -217.15900M | -249.02100M | -153.26000M | -117.57900M | -108.85000M |
| Ebitda | -193.20500M | -247.04600M | -154.19500M | -116.26200M | -106.08300M |
| Depreciation and amortization | 23.95M | 1.98M | -0.93500M | 1.32M | 2.77M |
| Non operating income net other | - | 6.58M | -0.93500M | 1.32M | 2.77M |
| Operating income | -217.15900M | -249.02100M | -153.26000M | -117.57900M | -108.85000M |
| Other operating expenses | 452.01M | 452.59M | 285.59M | 207.68M | 163.24M |
| Interest expense | 0.00500M | 0.08M | 0.37M | 0.79M | 1.29M |
| Tax provision | 1.15M | -10.41100M | -1.93000M | 0.38M | 0.29M |
| Interest income | 14.37M | 3.06M | 0.43M | 1.50M | 3.03M |
| Net interest income | 14.36M | 2.98M | 0.07M | 0.71M | 1.74M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | 22.50M | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1.15M | -10.41100M | -1.93000M | 0.38M | 0.29M |
| Total revenue | 245.11M | 203.56M | 132.33M | 90.10M | 54.38M |
| Total operating expenses | 296.63M | 333.26M | 204.97M | 146.27M | 115.81M |
| Cost of revenue | 155.38M | 119.33M | 80.62M | 61.41M | 47.43M |
| Total other income expense net | -10.92300M | 20.75M | -0.76800M | -21.97000M | 1.47M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -204.61800M | -217.86300M | -152.09800M | -139.93100M | -107.66900M |
| Net income applicable to common shares | - | -217.86300M | -152.09800M | -139.93100M | -107.66900M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Total assets | 776.40M | 961.38M | 702.10M | 398.88M | 186.99M |
| Intangible assets | 54.48M | 59.74M | 18.26M | 0.31M | 0.51M |
| Earning assets | - | - | - | - | - |
| Other current assets | 11.72M | 11.91M | 8.28M | 6.20M | 2.59M |
| Total liab | 152.97M | 171.99M | 121.28M | 62.62M | 34.91M |
| Total stockholder equity | 623.43M | 789.38M | 580.82M | 336.26M | 152.08M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 7.80M | 53.45M | 9.62M | 2.61M | 0.82M |
| Common stock | - | 789.38M | 580.82M | 336.26M | -186.99400M |
| Capital stock | - | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Retained earnings | -1033.03400M | -828.41600M | -610.55300M | -458.45500M | -318.52400M |
| Other liab | - | 0.06M | 5.07M | 0.35M | 0.16M |
| Good will | 85.81M | 85.81M | 22.43M | 1.14M | 1.14M |
| Other assets | - | -0.00100M | 49.90M | 3.40M | 4.38M |
| Cash | 286.47M | 378.69M | 465.83M | 93.67M | 46.73M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 73.32M | 90.66M | 63.05M | 36.03M | 30.35M |
| Current deferred revenue | 36.57M | 3.48M | 28.76M | 18.85M | 16.44M |
| Net debt | -192.40100M | -283.77500M | -402.90800M | -57.68500M | -39.00200M |
| Short term debt | 14.90M | 13.64M | 9.77M | 9.74M | 3.33M |
| Short long term debt | - | - | 1.55M | 3.33M | 3.33M |
| Short long term debt total | 94.07M | 94.91M | 62.92M | 35.98M | 7.73M |
| Other stockholder equity | 1657.22M | 1619.64M | 1190.83M | 794.63M | 283.43M |
| Property plant equipment | - | 214.39M | 44.12M | 25.47M | 20.84M |
| Total current assets | 424.26M | 596.48M | 546.50M | 334.87M | 160.13M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 789.38M | 540.12M | 334.82M | 150.44M |
| Short term investments | 49.94M | 126.28M | 12.03M | 196.34M | 91.37M |
| Net receivables | 44.06M | 40.29M | 28.55M | 26.38M | 12.10M |
| Long term debt | - | - | - | 1.40M | 4.40M |
| Inventory | 32.06M | 39.31M | 31.80M | 12.29M | 7.33M |
| Accounts payable | 14.05M | 20.09M | 14.90M | 4.83M | 9.76M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.75600M | -1.84300M | 0.55M | 0.09M | 0.18M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -828.41600M | -610.55300M | -458.45500M | -318.52400M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 8.49M | 4.96M | 9.20M | 3.40M | 4.38M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 352.15M | 364.89M | 155.60M | 64.01M | 26.86M |
| Capital lease obligations | 94.07M | 94.91M | 61.37M | 31.25M | - |
| Long term debt total | - | - | - | 1.40M | 4.40M |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Investments | - | -117.15800M | 183.70M | -104.78200M | -90.07400M |
| Change to liabilities | - | 7.38M | 19.02M | -1.71100M | 12.30M |
| Total cashflows from investing activities | - | -232.93000M | 156.16M | -114.65000M | -104.81000M |
| Net borrowings | - | -1.55800M | -3.33300M | -3.33300M | -2.50000M |
| Total cash from financing activities | 0.91M | 270.53M | 329.18M | 303.73M | 158.58M |
| Change to operating activities | - | 4.42M | 3.77M | -0.44200M | 7.71M |
| Net income | -204.61800M | -217.86300M | -152.09800M | -139.93100M | -107.66900M |
| Change in cash | -90.97800M | -87.10000M | 373.11M | 46.85M | -34.13900M |
| Begin period cash flow | 380.26M | 467.36M | 94.25M | 47.40M | 81.54M |
| End period cash flow | 289.28M | 380.26M | 467.36M | 94.25M | 47.40M |
| Total cash from operating activities | -142.47400M | -124.38500M | -112.24400M | -142.25500M | -87.93700M |
| Issuance of capital stock | - | 269.82M | 323.86M | 295.56M | 156.21M |
| Depreciation | 29.31M | 16.51M | 9.75M | 6.68M | 6.11M |
| Other cashflows from investing activities | - | -13.91500M | -0.48300M | - | 0.02M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 7.24M | -7.53600M | -19.48900M | -4.95600M | -1.30200M |
| Change to account receivables | -4.32000M | -9.62200M | -2.20200M | -14.27200M | -6.68500M |
| Sale purchase of stock | -4.40500M | -7.75400M | -10.84900M | -2.42100M | 161.08M |
| Other cashflows from financing activities | 5.32M | 10.02M | 19.50M | 13.92M | 4.87M |
| Change to netincome | - | 82.32M | 37.10M | 17.25M | 11.59M |
| Capital expenditures | 27.78M | 101.86M | 27.06M | 9.87M | 14.76M |
| Change receivables | - | -9.62200M | -2.20200M | -14.27200M | -6.68500M |
| Cash flows other operating | - | 10.67M | -5.00200M | -5.28000M | -1.31800M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -86.78100M | 373.09M | 46.83M | -34.16900M |
| Change in working capital | 0.41M | -5.35600M | -9.38100M | -25.17600M | 3.00M |
| Stock based compensation | 30.28M | 79.66M | 37.00M | 17.10M | 11.17M |
| Other non cash items | 2.56M | 2.66M | 1.86M | -0.70700M | 0.52M |
| Free cash flow | -170.25300M | -226.24200M | -139.30500M | -152.12300M | -102.69400M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience Corp |
-0.895 1.85% | 47.47 | - | - | 8.25 | 3.25 | 7.27 | -10.2325 |
| TMO Thermo Fisher Scientific Inc |
-0.26 0.04% | 598.76 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
1.49 0.57% | 264.95 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| IDXX IDEXX Laboratories Inc |
-5.6 1.02% | 542.93 | 55.57 | 53.76 | 12.50 | 34.56 | 12.72 | 38.21 |
| IQV IQVIA Holdings Inc |
2.29 0.98% | 235.97 | 37.82 | 19.68 | 2.76 | 7.20 | 3.61 | 17.03 |
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
681 Gateway Boulevard, South San Francisco, CA, United States, 94080
| Name | Title | Year Born |
|---|---|---|
| Dr. Emily Marine Leproust Ph.D. | Co-Founder, Chairman & CEO | 1973 |
| Dr. Patrick John Finn Ph.D. | Pres & COO | 1972 |
| Mr. James M. Thorburn | Chief Financial Officer | 1956 |
| Dr. William Charles Banyai Ph.D. | Sr. VP of Advanced Devel., GM of Data Storage & Director | 1955 |
| Mr. Kevin B. Yankton | VP & Chief Accounting Officer | 1967 |
| Mr. Siyuan Chen | Chief Technology Officer | NA |
| Dr. Aaron K. Sato Ph.D. | Chief Scientific Officer | NA |
| Mr. Dennis Cho | Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer | 1971 |
| Ms. Paula Green | Sr. VP of HR | 1968 |
| Ms. Erin Smith | Sr. VP of Gov. Affairs & Public Policy | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...